Advertisement


Bradley R. Prestidge, MD, on Prostate Cancer: Initial Findings of NRG Oncology/RTOG 0232

2016 ASTRO Annual Meeting

Advertisement

Bradley R. Prestidge, MD, of Bon Secours VA Health System, summarizes his plenary lecture on this phase III trial comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostate cancer. (Plenary Lecture 1, Presentation 7)



Related Videos

Breast Cancer

Meena Moran, MD, on Ductal Carcinoma In Situ: Improving Local Control

Meena Moran, MD, of Yale University, discusses an analysis from 10 pooled academic institutions that showed a radiation boost after whole breast radiation therapy improves local control of this disease. (Abstract 324)

Head and Neck Cancer

Takeshi Kodaira, MD, PhD, on Glottic Cancer: Results of a Japan Clinical Oncology Group Study

Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)

Issues in Oncology

Louis Harrison, MD, on Radiation Oncology and the Future of Health Care

Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.

Prostate Cancer

Paul L. Nguyen, MD, on Prostate Cancer: High-Risk Disease, Brachytherapy, And Hormones

Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)

Issues in Oncology

Howard M. Sandler, MD, on RTOG’s Past and NRG’s Future

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)

Advertisement

Advertisement




Advertisement